VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Tabernero on New Characterizations in CRC

Josep Tabernero, MD, PhD
Published: Friday, Oct 18, 2013

Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

Tabernero says physicians have been working on two important colorectal cancer characterizations over the year. While physicians were aware that KRAS mutations played a role as a narrative primitive biomarker for patients with colorectal cancer, Tabernero says, physicians have now discovered that KRAS and NRAS mutations are important narrative primitive factors. Tabernero says that this discovery will allow physicians to focus more on a selective population of patients that will benefit more from EGFR treatments.

Physicians have also made new discoveries concerning BRAF mutated colorectal cancers, which accounts for 5-10% of patients with colorectal cancer, Tabernero says.

Tabernero says physicians are developing important treatment strategies by combining BRAF V600E inhibitor with EGFR inhibitors and other pathway inhibitors. Studies are currently underway to test different treatment strategies in this pathway. More and more, physicians are characterizing different populations of colorectal cancer, Tabernero says, to try to provide these patients with the best treatment options. 
Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

Tabernero says physicians have been working on two important colorectal cancer characterizations over the year. While physicians were aware that KRAS mutations played a role as a narrative primitive biomarker for patients with colorectal cancer, Tabernero says, physicians have now discovered that KRAS and NRAS mutations are important narrative primitive factors. Tabernero says that this discovery will allow physicians to focus more on a selective population of patients that will benefit more from EGFR treatments.

Physicians have also made new discoveries concerning BRAF mutated colorectal cancers, which accounts for 5-10% of patients with colorectal cancer, Tabernero says.

Tabernero says physicians are developing important treatment strategies by combining BRAF V600E inhibitor with EGFR inhibitors and other pathway inhibitors. Studies are currently underway to test different treatment strategies in this pathway. More and more, physicians are characterizing different populations of colorectal cancer, Tabernero says, to try to provide these patients with the best treatment options. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x